loading
Summit Therapeutics Inc stock is traded at $27.04, with a volume of 884.00K. It is up +1.40% in the last 24 hours and up +27.42% over the past month. Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$26.74
Open:
$26.98
24h Volume:
884.00K
Relative Volume:
0.20
Market Cap:
$20.10B
Revenue:
$956.00K
Net Income/Loss:
$-221.32M
P/E Ratio:
-84.48
EPS:
-0.32
Net Cash Flow:
$-142.25M
1W Performance:
-3.20%
1M Performance:
+27.42%
6M Performance:
+21.27%
1Y Performance:
+153.65%
1-Day Range:
Value
$26.78
$27.69
1-Week Range:
Value
$26.50
$29.07
52-Week Range:
Value
$8.88
$36.91

Summit Therapeutics Inc Stock (SMMT) Company Profile

Name
Name
Summit Therapeutics Inc
Name
Phone
305-203-2034
Name
Address
601 BRICKELL KEY DRIVE, MIAMI
Name
Employee
159
Name
Twitter
@summitplc
Name
Next Earnings Date
2025-02-24
Name
Latest SEC Filings
Name
SMMT's Discussions on Twitter

Compare SMMT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SMMT
Summit Therapeutics Inc
27.07 20.39B 956.00K -221.32M -142.25M -0.32
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
473.23 118.34B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
559.69 60.31B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
345.09 42.35B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
606.74 36.43B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
301.70 31.87B 3.81B -644.79M -669.77M -6.24

Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-01-25 Initiated UBS Buy
Jun-11-25 Initiated Leerink Partners Underperform
Mar-26-25 Upgrade Citigroup Neutral → Buy
Mar-21-25 Initiated Cantor Fitzgerald Overweight
Mar-12-25 Initiated Evercore ISI Outperform
Feb-28-25 Initiated Goldman Buy
Jan-08-25 Initiated Truist Buy
Dec-11-24 Initiated Wells Fargo Overweight
Dec-06-24 Initiated Jefferies Buy
Nov-04-24 Initiated JMP Securities Mkt Outperform
Sep-27-24 Downgrade Citigroup Buy → Neutral
Aug-12-24 Initiated H.C. Wainwright Buy
May-07-24 Initiated Citigroup Buy
Mar-26-24 Initiated Stifel Buy
Jun-28-18 Downgrade Janney Buy → Neutral
May-02-18 Initiated Janney Buy
Apr-12-18 Reiterated Needham Buy
Feb-13-18 Initiated BTIG Research Buy
Jan-04-18 Initiated SunTrust Buy
Dec-01-17 Resumed H.C. Wainwright Buy
Nov-16-16 Reiterated RBC Capital Mkts Outperform
Oct-05-16 Reiterated Needham Buy
Sep-16-16 Initiated H.C. Wainwright Buy
Mar-30-15 Initiated Needham Buy
Mar-30-15 Initiated Oppenheimer Outperform
View All

Summit Therapeutics Inc Stock (SMMT) Latest News

pulisher
05:36 AM

How high can Summit Therapeutics Inc. stock goProfit Target Planning with Exit Confidence - Newser

05:36 AM
pulisher
02:17 AM

Summit Therapeutics Inc. recovery potential after sell offConsistent Return Setup with Exit Strategy - Newser

02:17 AM
pulisher
Jul 29, 2025

Is Summit Therapeutics Inc. Stock a Good Fit for Conservative InvestorsSmart Trade Mapping with Entry Details - Newser

Jul 29, 2025
pulisher
Jul 29, 2025

Is Summit Therapeutics Inc. stock a growth or value playFree Day Trading Signals With High Precision - Newser

Jul 29, 2025
pulisher
Jul 28, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Summit Therapeutics Inc. (SMMT) And Encourages Shareholders to Connect - ACCESS Newswire

Jul 28, 2025
pulisher
Jul 28, 2025

Summit Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada

Jul 28, 2025
pulisher
Jul 28, 2025

Is Summit Therapeutics Inc. stock poised for growthTechnical Setup Guide for Daily Watchlist - Newser

Jul 28, 2025
pulisher
Jul 28, 2025

Why is Summit Therapeutics Inc. stock attracting strong analyst attentionRapid-fire capital growth - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Summit Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily

Jul 28, 2025
pulisher
Jul 28, 2025

Ivonescimab's Dual-Action Revolution: A Catalyst for Akeso and Summit Therapeutics in the $500M+ Lung Cancer Market - AInvest

Jul 28, 2025
pulisher
Jul 27, 2025

Does Summit Therapeutics Inc. stock perform well during market downturnsBuild a portfolio that withstands market volatility - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - MarketScreener

Jul 27, 2025
pulisher
Jul 27, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - PR Newswire

Jul 27, 2025
pulisher
Jul 27, 2025

Is Summit Therapeutics Inc. Stock Overbought or Oversold RSI Indicator AnalysisVolume Spike Monitors - Newser

Jul 27, 2025
pulisher
Jul 27, 2025

When is Summit Therapeutics Inc. stock expected to show significant growthAchieve consistent profits with proven strategies - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 25, 2025

Summit Therapeutics Jumps 4% As Technicals Signal Bullish Breakout Potential - AInvest

Jul 25, 2025
pulisher
Jul 25, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Summit Therapeutics Inc. (SMMT) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Jul 25, 2025
pulisher
Jul 25, 2025

Summit Therapeutics Soars 4.64%—Could This Biotech Breakthrough Signal a Game-Changer? - AInvest

Jul 25, 2025
pulisher
Jul 24, 2025

What drives Summit Therapeutics Inc. stock priceConsistent double returns - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Summit Therapeutics Inc. (SMMT) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Jul 24, 2025
pulisher
Jul 24, 2025

Bank of New York Mellon Corp Has $6.57 Million Stock Holdings in Summit Therapeutics PLC (NASDAQ:SMMT) - Defense World

Jul 24, 2025
pulisher
Jul 24, 2025

Will Summit Therapeutics Inc. stock benefit from AI tech trendsTriple-digit growth rates - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings - MSN

Jul 24, 2025
pulisher
Jul 24, 2025

Summit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Jul 24, 2025
pulisher
Jul 23, 2025

Is Summit Therapeutics Inc. a good long term investmentHigh-octane financial growth - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Jul 23, 2025
pulisher
Jul 23, 2025

Meet the Biotech Stock That Rocketed 775% Higher - AOL.com

Jul 23, 2025
pulisher
Jul 22, 2025

What analysts say about Summit Therapeutics Inc. stockExplosive capital appreciation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Summit Therapeutics Inc. (SMMT) And Encourages Investors to Connect - ACCESS Newswire

Jul 22, 2025
pulisher
Jul 22, 2025

3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results - The Motley Fool

Jul 22, 2025
pulisher
Jul 22, 2025

Summit Therapeutics Inc. Stock Analysis and ForecastDouble-digit growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Summit Therapeutics Inc. (SMMT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Jul 21, 2025
pulisher
Jul 21, 2025

This Healthcare Stock's Revolutionary Drug Could Make Early Investors Rich - Yahoo Finance

Jul 21, 2025
pulisher
Jul 21, 2025

3 Monster Stocks in the Making to Buy Right Now - The Globe and Mail

Jul 21, 2025
pulisher
Jul 20, 2025

Trading (SMMT) With Integrated Risk Controls - news.stocktradersdaily.com

Jul 20, 2025
pulisher
Jul 20, 2025

Summit Therapeutics PLC (NASDAQ:SMMT) Shares Acquired by Cerity Partners LLC - Defense World

Jul 20, 2025
pulisher
Jul 19, 2025

Published on: 2025-07-19 02:49:19 - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Summit Therapeutics Inc. (SMMT) And Encourages Investors to Reach Out - ACCESS Newswire

Jul 18, 2025

Summit Therapeutics Inc Stock (SMMT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Summit Therapeutics Inc Stock (SMMT) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
DUGGAN ROBERT W
Co-Chief Executive Officer
May 30 '25
Option Exercise
2.64
74,545
196,799
555,754,696
$107.16
price up icon 2.07%
$37.43
price up icon 0.30%
$77.95
price up icon 0.71%
$111.50
price up icon 0.02%
biotechnology ONC
$300.93
price down icon 1.39%
Cap:     |  Volume (24h):